A Study of AZD0120 in Autoimmune Diseases
← catalyst calendarNCT07295847 · readout in 552 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
27estimated
Sites
22
Countries
Australia, Germany, Spain +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-09 | actual | When the study began enrolling |
| Primary completion | 2028-02-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-22 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathies
- Rheumatoid Arthritis
Intervention
- Biological: AZD0120 — also filed as GC012F
Primary outcome
what the primary-completion date above is the date OFNumber of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)
measured 1 year
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed